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Abstract 
Objective: Deferred revascularisation based upon fractional flow reserve (FFR >0.80) is associated with a low inci‑
dence of target lesion failure (TLF). Whether deferred revascularisation is also as safe in diabetes mellitus (DM) patients 
is unknown.
Methods: All DM patients and the next consecutive Non‑DM patients who underwent a FFR‑assessment between 
1/01/2010 and 31/12/2013 were included, and followed until 1/07/2015. Patients with lesions FFR >0.80 were ana‑
lysed according to the presence vs. absence of DM, while patients who underwent index revascularisation in FFR‑
assessed or other lesions were excluded. The primary endpoint was the incidence of TLF; a composite of target lesion 
revascularisation (TLR) and target vessel myocardial infarction (TVMI).
Results: A total of 250 patients (122 DM, 128 non‑DM) who underwent deferred revascularisation of all lesions 
(FFR >0.80) were compared. At a mean follow up of 39.8 ± 16.3 months, DM patients compared to non‑DM had a 
higher TLF rate, 18.1 vs 7.5 %, logrank p ≤ 0.01, Cox regression‑adjusted HR 3.65 (95 % CI 1.40–9.53, p < 0.01), which 
was largely driven by a higher incidence of TLR (17.2 vs. 7.5 %, HR 3.52, 95 % CI 1.34–9.30, p = 0.01), whilst a non‑sig‑
nificant but numerically higher incidence of TVMI (6.1 vs. 2.0 %, HR 3.34, 95 % CI 0.64–17.30, p = 0.15) was observed.
Conclusions: This study, the largest to directly compare the clinical outcomes of FFR‑guided deferred revasculari‑
sation in patients with and without DM, shows that DM patients are associated with a significantly higher TLF rate. 
Whether intravascular imaging, additional invasive haemodynamics or stringent risk factor modification may impact 
on this higher TLF rate remains unknown.
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Background
Fractional flow reserve (FFR) has an established and 
extensive clinical evidence base, and represents now the 
gold-standard invasive functional assessment of coronary 
lesions. Compared to angiographic assessment alone, 
FFR guided revascularisation results in more judicious 
stent placement, with subsequent cost reduction and 
superior clinical outcomes [1–3]. Furthermore, based on 
landmark trials, deferred revascularisation in haemody-
namic non-significant lesions (FFR  >0.80) is associated 
with excellent clinical outcomes and low rates of major 
adverse cardiac events including target lesion revascular-
isation (TLR) and myocardial infarction (MI) [1, 3].
However, longer-term data on deferred revasculari-
sation primarily relates to patients with stable angina, 
with a low proportion of diabetes mellitus (DM) 
patients represented [1, 3]. DM patients have acceler-
ated coronary atherosclerosis, an increased prevalence 
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of microcirculatory dysfunction and a greater bur-
den of high-risk plaque compared to non-DM patients 
[4–7]. Therefore, the medium to long-term outcomes of 
deferred revascularisation in high-risk populations with 
more rapidly progressive coronary atherosclerosis, such 
as patients with DM has not been thoroughly evalu-
ated in previous studies. This particular study focuses 
on the clinical outcomes in patients with lesions which 
were non-haemodynamically significant (FFR  >0.80) 




In order to assess the safety and efficacy of FFR-guided 
deferred revascularisation, from a total of 3379 patients 
who underwent FFR-assessment from January 2010 
until December 2013, we identified all DM patients as 
well as the next consecutive non-DM patients and fol-
lowed these patients until 1/7/2015 (Fig.  1). In order to 
avoid contamination of endpoints from events occurring 
from revascularised lesions, we further excluded all 
patients where a revascularisation took place in the FFR 
assessed and/or other lesions, so that only patients with 
FFR-negative lesions were included and further analysed. 
As shown in Fig.  1, the two groups analysed were: DM 
patients with FFR-negative lesions (FFR  >0.80) where 
revascularisation was deferred [FFR(-)DM] vs. non-DM 
patients with FFR-negative lesions patients where revas-
cularisation was deferred [FFR(-)NonDM].
Baseline demographics were obtained utilising elec-
tronic medical records, as was data relating to the FFR 
measurement and baseline angiography. Follow up events 
were obtained primarily from the electronic patient 
record and by telephone contact with primary care phy-
sicians or direct contact with patients where required. 
Follow up was complete in all FFR-assessed patients. FFR 
assessment was systematically performed in patients with 
intermediate native coronary lesions ranging from 40 to 
80 % diameter stenosis, where no prior non-invasive test 
of ischaemia was performed or when these were incon-
clusive. FFR was not performed for culprit lesions in MI, 
3,379 Patients undergoing FFR-guided revascularisation
1/1/2010-31/12/2013
& next consecutive 294 Non-DM Patients294 DM Patients
172 Patients excluded:
89 Patients-all lesions FFR 0.80  & 
complete revascularisation
83 Patients- with 1 lesion(s) FFR 






76 Patients with all lesions FFR 
0.80  & complete revascularisation
78 Patients with 1 lesion(s) FFR 
0.80 & underwent 
revascularisation




Fig. 1 Study‑flow chart. FFR fractional flow reserve, DM diabetes mellitus
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lesions with TIMI flow <3, or when the operator deemed 
a lesion to be clearly of haemodynamic significance.
The FFR was performed using a standard coronary 
pressure wire (PressureWire Certus, St. Jude Medical or 
Combowire, Volcano Corp). As per standard protocol, 
intravenous adenosine was infused at a rate of 140  μg/
kg/min to achieve maximum hyperaemia. Both baseline 
FFR and maximum hyperaemic FFR values were noted for 
each lesion. After steady-state hyperaemia was achieved, 
the FFR was calculated as the ratio of mean distal intrac-
oronary pressure measured by the pressure wire, and the 
mean arterial pressure measured through the coronary 
guiding catheter. In situations where multiple FFR meas-
urements of a lesion were made, the lowest measurement 
was used as the final assessment. A cut-off value of >0.80 
was taken to imply a functionally non-significant coronary 
stenosis and the patient underwent deferred revasculari-
sation and continued guideline directed medical therapy.
Visual assessment of reference vessel diameter, diameter 
stenosis, American Heart Association/American Cardiol-
ogy College (AHA/ACC) lesion type and the presence of 
calcification and diffuse disease were noted for all lesions 
by two independent interventional cardiologists. Both 
reviewers were blinded to the clinical outcomes. A third 
interventional cardiologist was used in cases where dis-
cordance arose. In addition, the syntax score (SS) was cal-
culated, based upon the index (time of FFR-measurement) 
coronary angiogram, by scoring all lesions >1.5 mm with 
at least 50 % diameter stenosis [8]. For those patients with 
a prior coronary artery bypass graft (CABG), no SS was 
calculated. The local Institutional Review Board approved 
this study and waived the requirement for written consent 
to an institutional registry.
Endpoints and definitions
Diabetes mellitus was defined by patient history and clas-
sified by treatment with diet, exercise, oral anti-diabetic 
medication or insulin. The primary endpoint was the 
incidence of target lesion failure (TLF), defined as a com-
posite of target lesion revascularisation (TLR) and target 
vessel myocardial infarction (TVMI). Target lesion was 
defined as the lesion(s) in which the FFR measurement 
was performed, with TLR referring to revascularisa-
tion in that lesion(s). Myocardial Infarction was defined 
according to established guidelines [9]. Target vessel 
myocardial infarction (TVMI) refers to the occurrence of 
myocardial infarction within the vessel in which the FFR 
was assessed.
Statistical methods
Continuous variables are summarised as mean ± stand-
ard deviation. Discrete variables are summarised as fre-
quency (group percentage). Group comparisons were 
tested using Student’s t test or Mann–Whitney U test 
for continuous variables and Pearson’s x2 test for discrete 
data. Kaplan–Meier estimates were used to estimate sur-
vival curves, and the log-rank test was used to establish 
differences between groups. Cox proportional hazards 
multiple regression models were used to estimate differ-
ences in time to event between the two groups expressed 
as hazard ratio’s (HR) with 95  % confidence intervals, 
adjusted for several patient characteristics. In the explor-
atory model; gender, age, renal insufficiency, hyperten-
sion, hypercholesterolaemia, prior MI, prior PCI, prior 
CABG, smoking, reference vessel diameter, diameter ste-
nosis, the presence of calcific and diffuse disease, and the 
absolute hyperaemic FFR value were analysed. A p value 
of  <0.05 was considered significant. All analyses were 
conducted using SPSS 23 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
As shown in Fig. 1, a total of 588 patients who underwent 
FFR assessment and fulfilled enrolment criteria were ana-
lysed, of which 250 patients (329 lesions) had only lesions 
with an FFR >0.80 and were further treated medically. Of 
these, 122 patients (157 lesions) and 128 patients (172 
lesions) formed the FFR(-)DM group and FFR(-)NonDM 
groups respectively. The mean length of follow up was 
39.8 ± 16.3 months (±SD).
Baseline clinical and angiographic characteristics 
are noted in Table  1. The average age of patients was 
67.6 ± 10.2 years, however patients were older (70.4 ± 9 
vs. 65.0 ± 10.7, p < 0.01) in the FFR(-)DM group. Over-
all, the baseline characteristics were well matched in both 
groups, however more patients had hypertension (95.9 
vs. 80.5  %, p  <  0.01), renal insufficiency (16.4  vs. 1.6  %, 
p  <  0.01) and prior CABG (17.2  vs. 7.8  %, p =  0.02) in 
the FFR(-)DM group. Both the mean Syntax Score (SS) 
(8.71 ± 6.43 vs. 8.68 ± 5.46, p = 0.75) and the mean FFR 
result (0.88 ± 0.05 vs. 0.88 ±0.05, p = 0.24) was similar 
in both groups. Within the FFR(-)DM group, the mean 
HbA1c was 52.6 ± 9.1 mmol/mol.
As shown in Table  2, American Heart Association/
American Cardiology College (AHA/ACC) lesion type 
A was more frequent in the FFR(-)NonDM group (lesion 
level; 23.8 vs. 14.6 %, p = 0.02), whilst lesion types B2 and 
C were more common in the FFR(-)DM group, (34.4 vs. 
22.1  %). Furthermore, patients with DM had more dif-
fuse disease (22.3 vs. 11 %, p = 0.03). However, in both 
groups calcified lesions were similarly observed (19.7 vs. 
18.6 %, p = 0.94) and both the reference vessel diameter 
(2.98  ±  0.45 vs. 3.02  ±  0.44, p  =  0.41) and percentage 
diameter stenosis (58.8 % ± 8.3 vs. 59.1 % ± 7.0, p = 0.47) 
were similar in the FFR(-)DM and FFR(-)NonDM groups 
respectively.
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Clinical outcomes
The results of the clinical outcomes are shown in Table 3 
and Figs. 2 and 4 by means of Kaplan–Meier curves. The 
primary outcome, TLF, was observed more frequently in 
the FFR(-)DM group, (18.1 vs. 7.5 %, log-rank p < 0.01), 
Cox-regression adjusted HR 3.65 (95  % CI 1.40–9.53, 
p < 0.01), Fig. 2. In addition the occurrence of TLR was 
significantly higher in the FFR(-)DM group, adjusted 
HR 3.52 (95 % CI 1.34–9.30), p = 0.01, Fig. 3. In the DM 
group, 11/16 TLR events were as a result of TVMI or 
positive repeat FFR/ischaemic detection. The remaining 
5/16 events were due to clear angiographic progression 
or unstable angina pectoris at presentation. A similar HR 
3.34 (95 % CI 0.64–17.3), (p = 0.15), Table 3, Fig. 4, was 
also observed for TVMI, however due to lack of power, 
statistical significance was not reached but the trend is 
clear. Amongst those DM patients with TLF, HbA1c was 
higher (57.3 ±  14.4 vs. 51.8 ±  7.7 mmol/mol), however 
this did not reach statistical significance (p = 0.10).
Discussion
The major finding of this analysis, the largest to date to 
directly compare the real-world clinical outcomes of 
haemodynamically non-significant (FFR  >0.80) lesions 
which were treated medically in patients with versus 
without DM, shows that DM patients have a significantly 
higher risk of medium to long-term TLF. The observed 
higher TLF incidence in DM patients was driven pri-
marily by efficacy events (TLR), whilst a trend for safety 
(TVMI) events, which did not reach statistical signifi-
cance, was observed.
Presently FFR is the gold standard invasive assessment 
of intermediate coronary lesions, with an extensive data 
Table 1 Baseline clinical characteristics
Renal insufficiency was defined as an estimated glomerular filtration rate, 
eGFR <60 mL/min
LV left ventricular, CAD coronary artery disease, MI myocardial infarction, PCI 
percutaneous coronary intervention, CABG coronary artery bypass graft
FFR(-)DM FFR(-)NonDM p value
n = 122 n = 128
Age, years, mean ± SD 70.4 ± 9.0 65.0 ± 10.7 <0.01
Gender, male,  % (n) 59 (72) 62.5 (80) 0.57
Diabetes mellitus,  % (n) 100 (122) 0 (0)
Insulin‑treated,  % (n) 41.8 (51) 0 (0)
LV ejection fraction, mean ± SD 52.8 ± 10.6 51.8 ± 10.6 0.73
Multi‑vessel CAD,  % (n) 24.6 (30) 29.7 (38) 0.56
Family history of CAD,  % (n) 32.8 (40) 32.8 (42) 0.98
Hypertension,  % (n) 95.9 (117) 80.5 (103) <0.01
Hypercholesterolemia, n  % (n) 95.9 (117) 93 (119) 0.31
Current smoking,  % (n) 15.6 (19) 21.1 (27) 0.26
Renal Insufficiency,  % (n) 16.4 (20) 1.6 (2) <0.01
Prior MI,  % (n) 44.3 (54) 32 (41) 0.05
Prior PCI,  % (n) 40.2 (49) 34.4 (44) 0.34
Prior CABG,  % (n) 17.2 (21) 7.8 (10) 0.02
Table 2 Baseline angiographic, FFR and lesion characteristics
FFR fractional flow reserve, AHA American Heart Association, ACC American College of Cardiology, CABG coronary artery bypass graft
a Visual assessment
FFR(-)DM n = 122 FFR(-)NonDM n = 128 p value
Syntax score, mean ± SD 8.71 ± 6.43 8.68 ± 5.46 0.75
Low scores (0–22),  % (n) 80.3 (98) 89.8 (115) 0.03
Intermediate scores (23–32),  % (n) 0.8 (1) 1.6 (2) >0.99
High scores (≥33),  % (n) 1.6 (2) 0.8 (1) 0.62
Unclassified, prior CABG,  % (n) 17.2 (21) 7.8 (10) 0.02
FFR performed in one lesion,  % (n) 77 (94) 70.3 (90) 0.23
FFR performed in two lesions  % (n) 17.2 (21) 25 (32) 0.13
FFR performed in three lesions,  % (n) 5.7 (7) 4.7 (6) 0.71
FFR result, mean ± SD 0.88 ± 0.05 0.88 ± 0.05 0.24
Lesion characteristics: at lesion level n = 157 n = 172
AHA/ACC lesion type classification:
Type A,  % (n) 14.6 (23) 23.8 (41) 0.02
Type B1,  % (n) 51 (80) 54.1 (93) 0.91
Type B2,  % (n) 25.5 (40) 19.2 (33) 0.17
Type C,  % (n) 8.9 (14) 2.9 (5) 0.07
Calcified lesion,  % (n) 19.7 (31) 18.6 (32) 0.94
Diffuse disease,  % (n) 22.3 (35) 11 (19) 0.03
Reference vessel diametera, mean ± SD (mm) 2.98 ± 0.45 3.02 ± 0.44 0.41
Percentage of diameter stenosisa, mean ± SD 58.79 ± 8.3 59.07 ± 7.0 0.47
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to support its use [1, 3, 10, 11]. The DEFER and FAME 
studies have shown that deferred revascularisation based 
on FFR guidance, is safe and associated with a favour-
able medium to long-term prognosis [1, 3]. However, in 
both these studies, a low proportion of DM patients were 
included. A 5-year rate of 8.9  % deferred lesion revas-
cularisation was noted in the DEFER study (FFR >0.75), 
whilst in the FAME study, the 2-year rate of TLR was 
3.2 % in FFR negative lesions, both findings being compa-
rable to TLR rates in the low-risk non-DM patients in our 
study. Similarly, the rates of MI observed in these stud-
ies (DEFER; 5-year MI rate 0  % in deferred lesions and 
FAME; 0.2 % 2-year MI rate in lesions >0.80) are similar 
to rates observed in the non-DM patients in our study.
Moreover, since FAME and DEFER, several other real-
world studies have indicated that the rate of TLR for 
deferred lesions may be higher than previously reported 
in randomised trials. Rieber et al. [12] reported in a group 
of 56 patients, 11 revascularisations over a 5-year period 
(TLR 10.7 %) and more recently, two larger studies, which 
included a proportion of patients with reduced LV func-
tion and also patients 1–7  days after ACS, have shown 
over a longer follow-up rates of TLR in deferred lesions 
of 20.6 % (n = 721, median follow up 48.7 months) and a 
3.8 % rate of deferred lesion MI (n = 721, mean follow up 
4 ± 2.3 years) [13, 14]. To date only one small single-cen-
tre study has directly examined the outcomes of deferred 
revascularisation in 40 DM and 96 non-DM patients, and 
whilst no significant difference was noted in the primary 
endpoint in that study, a numerically higher TLR rate 
(14.3 vs. 8.8 %) was noted over an average of 30 months 
follow-up [15]. Our results in the higher risk DM group 
are again comparable to the findings of these studies.
Recently, concerns regarding increased vascular resist-
ance and reduced vasodilative capacity due to chronic 
hyperglycaemia in DM patients have been raised [16]. 
Data from prior non-invasive studies which have assessed 
the microcirculatory function in patients with and with-
out DM, have shown that even in those DM patients 
without known coronary artery disease (CAD), the 
presence of an abnormal coronary flow reserve (CFR) is 
associated with poor outcomes, comparable to non-DM 
patients with known CAD [17]. Furthermore in the The 
Prediction of CK-MB release during successful stenting 
correlating with indicators of microvascular obstruction 
(PREDICT) trial, despite similar pre-PCI FFR values, DM 
patients compared to patients without, have lower CFR 
measurements [18].
In a study by Meuwissen et al. in patients undergoing 
combined FFR and CFR assessment, approximately 10 % 
Table 3 Outcome of primary endpoint and components
Event-rates shown are Kaplan–Meier event rate estimated, % (n of events)
HR adjusted hazard ratio
FFR(-)DM n = 122 FFR(-)Non-DM n = 128 Adjusted HR (95% CI) p value
Target lesion failure (TLF), % (n) 18.1 (17) 7.5 (6) 3.65 (1.40–9.53) <0.01
Target lesion revascularisation (TLR), % (n) 17.2 (16) 7.5 (6) 3.52 (1.34–9.30) 0.01
Target vessel MI (TVMI), % (n) 6.1 (6) 2.0 (2) 3.34 (0.64–17.30) 0.15
Fig. 2 Time‑to‑event estimates for target lesion failure according 
to FFR(‑)DM and FFR(‑)NonDM groups. TLF target lesion failure, CI 
confidence interval, HR hazard ratio (adjusted for age)
Fig. 3 Time‑to‑event estimates for target lesion revascularisation 
according to FFR(‑)DM and FFR(‑)NonDM groups. TLR target lesion 
revascularisation, CI confidence interval, HR hazard ratio (adjusted for 
age)
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of intermediate lesions when assessed as FFR >0.75, have 
an abnormal CFR defined as <2.0 and furthermore van de 
Hoef et al. have recently shown that in those patients in 
whom a FFR >0.80 is associated with an abnormal CFR 
(<2.0), the clinical outcomes are significantly worse than 
in patients with intact microcirculation [19, 20]. Recently 
Lee et  al. [21], confirmed these findings, also showing 
that DM patients with low CFR and high index of micro-
vascular resistance (IMR) have significantly elevated 
adverse cardiac event rates. Furthermore, whilst higher 
FFR values are associated with a lower incidence of 
adverse cardiac events in Non-DM patients with deferred 
revascularisation, it has recently been shown that FFR 
values do not differentiate future risk in DM patients [22]. 
As shown from these studies, FFR alone may be insuffi-
cient to ascertain the true haemodynamic significance of 
lesions in DM patients and therefore incorrectly lead to 
deferred revascularisation of lesions than may otherwise 
be associated with high adverse event rates. This may in 
part explain the results observed in the DM group in our 
study.
Additionally, it is known that compared to non-DM 
patients, atherosclerosis in diabetic patients is more often 
diffuse, with longer lesion length and is associated with 
a tendency toward negative vessel remodelling [4, 23]. 
Moreover, those DM patients in whom insulin treat-
ment is required have even worse outcomes [24]. Indeed 
as seen in the sub-group analysis from the providing 
regional observations to study predictors of events in the 
coronary tree (PROSPECT) study; radiofrequency intra-
vascular ultrasound assessed lesion length, plaque bur-
den, necrotic core, and calcium content were significantly 
greater among non-culprit lesions in DM as compared 
to non-DM patients [25, 26]. Indeed, recent evidence 
suggests that increased levels of plasma bone morphoge-
netic protein-2 (BMP-2) levels are found in DM patients 
and correlate positively with increased plaque burden, 
plaque calcification and negatively correlate with lumen 
volume [27]. Similarly, optical coherence tomography 
(OCT) studies, have shown that compared to non-DM 
patients, non-culprit lesions in DM patients have a larger 
lipid index, and when associated with elevated HbA1c 
levels, thin-cap fibroatheroma (TCFA) and macrophage 
infiltration is frequently observed [7]. In addition, in 
a second sub-group analysis of DM patients from the 
PROSPECT study, non-culprit lesions in DM patients 
when associated with a TCFA have a five-fold increased 
MACE rate at 3 years, whilst those DM patients without 
TCFA had a 3-year MACE rate comparable to non-DM 
patients [28]. Thus, as shown in the above mentioned 
studies, DM patients more frequently carry high-risk 
lesions, which due to faster progression are associated 
with higher adverse events, despite often being angio-
graphically mild and thus likely to be haemodynamically 
non-significant. Indeed, this may provide another plausi-
ble explanation for the findings of our analysis.
From the above, FFR assessment in combination with 
complementary haemodynamics (CFR and IMR) and 
also intravascular imaging may result in a more accurate 
deferred revascularisation and at the same time guide a 
more focused medical therapy strategy in DM patients. 
Previous studies have indicated that stringent risk fac-
tor modification in DM patients results in plaque ather-
oma volume regression similar to non-DM patients, and 
tighter glycaemic control can reduce the occurrence of 
recurrent ischaemic events [29–33].
Study limitations
The present study is a single-centre, non-randomised, 
observational study and thus the results should be con-
sidered as hypothesis generating. Cox proportional haz-
ards multiple regression models were used to correct for 
the baseline characteristics differences resulting from 
the lack of randomisation. Nonetheless, some residual 
confounding may persist despite a careful attempt to 
adjust for clinically relevant factors. In addition, the 
study took place in a region with a predominantly Cau-
casian population and data relating to race and ethnic-
ity was not captured in the registry, which may impact 
on the generalisability of our results. As was the case in 
the FAME II study, neither patients nor clinicians were 
blinded to the FFR result [11]. Therefore, knowledge of a 
prior borderline FFR measurement may have influenced 
the subsequent rates of TLR, however considering the 
retrospective nature of this study this was unavoidable. 
Nonetheless, the majority of TLR occurred in the setting 
of a subsequent acute coronary syndrome and in those 
Fig. 4 Time‑to‑event estimates for target vessel myocardial infarction 
according to FFR(‑)DM and FFR(‑)NonDM groups. TVMI target vessel 
myocardial infarction, CI confidence interval, HR hazard ratio (adjusted 
for age)
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patients with unstable and stable angina pectoris, the 
majority of revascularisations only took place after repeat 
FFR assessment/ischaemic detection. The combined use 
of coronary microcirculation assessment using CFR/IMR 
was not performed and the morphological composition 
of lesions in our study was unknown and therefore their 
impact on our results cannot be accurately assessed.
Finally, patients included in our study may be at higher 
risk than those enrolled in prior randomised trials, how-
ever we believe that our results are representative of the 
real world outcomes of FFR-guided deferred revasculari-
sation in patients with and without DM.
Conclusion
DM patients in whom revascularisation was deferred 
based upon FFR assessment have a higher TLF rate com-
pared to non-DM patients. Our results should be consid-
ered hypothesis generating and whether a combination 
of FFR with complementary haemodynamics (CFR and 
IMR) and intravascular imaging may result in more accu-
rate deferred revascularisation needs to be studied in 
larger dedicated studies.
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